What was the primary driver of revenue growth in the nine months ended October 2, 2016?

Revenue growth was primarily driven by a 7% increase in operational revenue, excluding the negative impact of foreign exchange. This growth was fueled by increased sales of key products like Apoquel®, successful new product launches, and contributions from recent acquisitions, notably Pharmaq and Abbott Animal Health.

How did the company manage its costs effectively?

Zoetis effectively managed costs by reducing both Cost of Sales and Selling, General, and Administrative (SG&A) expenses as a percentage of revenue. This was achieved through favorable product mix, lower global manufacturing and supply costs, the impact of the operational efficiency initiative, and reduced consulting fees and stand-up costs related to becoming an independent public company.

What is the impact of foreign exchange on Zoetis's financial results?

Foreign exchange had an unfavorable impact on Zoetis's reported revenue, decreasing it by 4% ($125 million) for the nine months ended October 2, 2016. This was primarily due to the depreciation of currencies like the Brazilian real and the Argentine peso. However, operational revenue growth, excluding this impact, was robust.

What is the company's financial position regarding debt and liquidity?

Zoetis maintained a strong financial position. Net cash provided by operating activities increased to $427 million for the nine months ended October 2, 2016. While the company used cash for investing and financing activities, including debt repayments and share repurchases, it had $651 million in cash and cash equivalents at the end of the period, and its revolving credit facility remained undrawn, indicating good liquidity.

ZTS 10-Q Filed Nov 3, 2016

Summary

Zoetis Inc. reported strong financial performance for the nine months ended October 2, 2016, with revenue increasing by 3% to $3.61 billion and net income attributable to Zoetis Inc. rising significantly to $667 million, a 110% increase compared to the same period in 2015. This growth was driven by a 7% increase in operational revenue, excluding foreign exchange impacts, fueled by key product sales like Apoquel®, new product launches, and strategic acquisitions such as Pharmaq and Abbott Animal Health. The company also demonstrated effective cost management, with Cost of Sales and Selling, General, and Administrative (SG&A) expenses decreasing as a percentage of revenue, contributing to an improved operating margin. Despite a 4% negative impact from foreign currency fluctuations on revenue, Zoetis maintained a solid financial position. The company's cash flow from operations remained robust, and it managed its debt effectively, repaying a portion of its long-term debt while maintaining ample liquidity. The strategic divestitures of certain non-core assets and ongoing operational efficiency initiatives also contributed to a more streamlined business. Overall, Zoetis is showing positive momentum, driven by product innovation, strategic growth initiatives, and disciplined cost control.

Key Highlights

1Revenue increased by 3% to $3.61 billion for the nine months ended October 2, 2016, compared to the prior year period.
2Net income attributable to Zoetis Inc. more than doubled, reaching $667 million for the nine months ended October 2, 2016, up from $317 million in the prior year.
3Operational revenue growth (excluding foreign exchange) was 7% for the nine months, driven by key products and acquisitions.
4Cost of sales and SG&A expenses decreased as a percentage of revenue, indicating improved operational efficiency.
5The company's cash flow from operations remained strong, providing ample liquidity.
6Zoetis successfully integrated recent acquisitions, including Pharmaq and certain assets of Abbott Animal Health, contributing to revenue growth.
7Restructuring charges decreased significantly year-over-year, reflecting progress in cost-reduction initiatives.

Zoetis Inc. Quarterly Report for Q3 Ended Oct 2, 2016

Summary

Key Highlights

Frequently Asked Questions